Optimer axes chairman, CFO and VP over misconduct related to stock options
This article was originally published in Scrip
Optimer Pharmaceuticals has removed chairman Dr Michael Chang from the company's board of directors for "his failure to identify and effectively manage compliance, record keeping and conflict of interest issues" in connection with stock options from the company's Taiwanese subsidiary, and fired chief financial officer John Prunty and vice-president Dr Youe-Kong Shue for their inaction regarding Dr Chang's alleged misconduct.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.